The early bactericidal activity of antituberculosis drugs

References

• Fenner F, Martin SP, Pierce CH. The enumeration of viable tubercle bacilli in cultures and infected tissues. Ann NY Acad Sci 1949;52(5):751-64
   PubMedGoogle Scholar
• Jensen KA, Kjaer I, Torning K, et al. Chemotherapy in tuberculosis. Acta Tuberc Scand 1954;29(2):95-105
   PubMedGoogle Scholar
• Joiner CL, Maclean KS, Chalmers DG, et al. Chemotherapy of pulmonary tuberculosis. Lancet 1953;265(6778):152-5
   PubMedGoogle Scholar
• Stewart SM, Murdoch JM, Crofton JW, et al. Pyrazinamide together with oxytetracycline in patients with tubercle bacilli resistant to streptomycin, PAS and isoniazid. Br J Tuberc Dis Chest 1957;51(2):158-67
   PubMedGoogle Scholar
• Hobby GL, Holman AP, Iseman MD, et al. Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother 1973;4(2):94-104
   PubMed Web of Science ®Google Scholar
• Yeager H Jr, Lacy J, Smith LR, et al. Quantitative studies of mycobacterial populations in sputum and saliva. Am Rev Respir Dis 1967;95(6):998-1004
   PubMedGoogle Scholar
• Brouet G, Chevallier J, Meeus Bith L, et al. Supplementary Clinical Study of Alpha–Propyl-Isonicotinic Acid Thioamide (1321 Th). Rev Tuberc Pneumol (Paris) 1965;29:133-58
   PubMedGoogle Scholar
• Cooperative controlled trial of thiocarlide (DATC), PAS and bed rest alone in short-term single-drug treatment in retreated cavitary pulmonary tuberculosis. Beitr Klin Erforsch Tuberk Lungenkr 1969;139(2):115-39
   PubMedGoogle Scholar
• Gyselen A. Rifampicin in the retreatment and original treatment of advanced pulmonary tuberculosis. Bull Int Union Tuberc 1970;43:60-3
   PubMedGoogle Scholar
• Schutz I. A comparison of rifampicin, ethambutol and PAS in short-term monotherapy. Preliminary results of the third cooperative study of the WATL. Acta Tuberc Pneumol Belg 1969;60(3):437-41
   PubMedGoogle Scholar
• Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121(6):939-49
   PubMed Web of Science ®Google Scholar
• Yajko DM, Wagner C, Tevere VJ, et al. Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay. J Clin Microbiol 1995;33(7):1944-7
   PubMedGoogle Scholar
• Botha FJ, Sirgel FA, Parkin DP, et al. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J 1996;86(2):155-8
   PubMed Web of Science ®Google Scholar
• Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;52(4):1522-4
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380(9846):986-93
   PubMed Web of Science ®Google Scholar
• Donald PR, Sirgel FA, Botha FJ, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997;156(3 Pt 1):895-900
   PubMedGoogle Scholar
• East African/British Medical Research Council. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa – third investigation: the effect of an initial streptomycin supplement. Tubercle 1966;47(1):1-32
   PubMedGoogle Scholar
• Donald PR, Parkin DP, Seifart HI, et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 2007;63(7):633-9
   PubMed Web of Science ®Google Scholar
• Donald PR, Sirgel FA, Venter A, et al. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis 2004;39(10):1425-30
   PubMed Web of Science ®Google Scholar
• Long MW, Snider DE Jr, Farer LS. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119(6):879-94
   PubMed Web of Science ®Google Scholar
• Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother 1993;32(6):867-75
   PubMedGoogle Scholar
• Chan SL, Yew WW, Ma WK, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis 1992;73(1):33-8
   PubMedGoogle Scholar
• Sirgel FA, Fourie PB, Donald PR, et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005;172(1):128-35
   PubMed Web of Science ®Google Scholar
• Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007;51(8):2994-6
   PubMed Web of Science ®Google Scholar
• Acocella G. Human bioavailability studies. Bull Int Union Tuberc Lung Dis 1989;64(1):38-40. discussion 40-32
   PubMedGoogle Scholar
• Boeree M, Diacon AH, Dawson R, et al. What is the “right” dose of rifampin? 20th Conference on Retroviruses and Opportunistic Infections, Paper 148LB; Atlanta, GA, USA; 2013. Abstract 128
   Google Scholar
• Dietze R, Teixeira L, Rocha LM, et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2001;45(7):1972-6
   PubMed Web of Science ®Google Scholar
• Dickinson L. Effect of streptomycin on experimental tuberculosis in guinea pigs. Br J Pharmacol Chemother 1947;2(1):23-6
   PubMed Web of Science ®Google Scholar
• Donald PR, Sirgel FA, Venter A, et al. The early bactericidal activity of amikacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2001;5(6):533-8
   PubMed Web of Science ®Google Scholar
• Tucker WB, Livings DG. Comparative efficacy of three streptomycin and para-aminosalicylic acid regimens of prolonged duration in patients with previously untreated pulmonary tuberculosis. Am Rev Tuberc 1955;72(6):756-82
   PubMedGoogle Scholar
• McCune RM Jr, McDermott W, Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956;104(5):763-802
   PubMedGoogle Scholar
• McDermott W, Ormond L, Muschenheim C, et al. Pyrazinamide-isoniazid in tuberculosis. Am Rev Tuberc 1954;69(3):319-33
   PubMedGoogle Scholar
• Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991;143(4 Pt 1):700-6
   PubMedGoogle Scholar
• Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985;131(3):352-6
   PubMedGoogle Scholar
• Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1997;156(3 Pt 1):901-5
   PubMedGoogle Scholar
• Pletz MW, De Roux A, Roth A, et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004;48(3):780-2
   PubMed Web of Science ®Google Scholar
• Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10(6):605-12
   PubMed Web of Science ®Google Scholar
• Chambers HF, Kocagoz T, Sipit T, et al. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis 1998;26(4):874-7
   PubMed Web of Science ®Google Scholar
• Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000;45(6):859-70
   PubMed Web of Science ®Google Scholar
• Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168(11):1342-5
   PubMed Web of Science ®Google Scholar
• Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003;167(10):1348-54
   PubMed Web of Science ®Google Scholar
• Kennedy N, Gillespie SH, Saruni AO, et al. Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. J Infect Dis 1994;170(3):713-16
   PubMed Web of Science ®Google Scholar
• Gillespie SH, Gosling RD, Uiso L, et al. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother 2005;56(6):1169-71
   PubMedGoogle Scholar
• Diacon AH, Maritz JS, Venter A, et al. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis 2010;29(12):1561-5
   PubMedGoogle Scholar
• Diacon AH, Maritz JS, Venter A, et al. Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect 2012;18(7):711-17
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52(8):2831-5
   PubMed Web of Science ®Google Scholar
• Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307(5707):223-7
   PubMed Web of Science ®Google Scholar
• Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007;3(6):323-4
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 2013;57(5):2199-203
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011;15(7):949-54
   PubMed Web of Science ®Google Scholar
• Hu Y, Coates AR, Mitchison DA. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008;12(1):69-73
   PubMed Web of Science ®Google Scholar
• Lenaerts AJ, Hoff D, Aly S, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by. r207910. Antimicrob Agents Chemother 2007;51(9):3338-45
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, du Bois J, et al. Phase. II dose-ranging trial of the early bactericidal activity of PA–824. Antimicrob Agents Chemother 2012;56(6):3027-31
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010;54(8):3402-7
   PubMed Web of Science ®Google Scholar
• Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367(16):1508-18
   PubMed Web of Science ®Google Scholar
• Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008;178(11):1180-5
   PubMed Web of Science ®Google Scholar
• Wallis RS, Diacon AH, Dawson R, et al. Safety, tolerability and early bactericidal activity in sputum of PNU-100480 (sutezolid) in patients with pulmonary tuberculosis. XIX International AIDS Conference 2012. Abstract A-452-0086-20755.
   Google Scholar
• Nuermberger E, Rosenthal I, Tyagi S, et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2006;50(8):2621-5
   PubMed Web of Science ®Google Scholar
• Hafner R, Cohn JA, Wright DJ, et al. Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group. Am J Respir Crit Care Med 1997;156(3 Pt 1):918-23
   PubMedGoogle Scholar
• Donald PR, Diacon AH. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb) 2008;88(Suppl 1):S75-83
   PubMed Web of Science ®Google Scholar
• Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther 2003;1(1):141-55
   PubMedGoogle Scholar
• Mitchison DA, Sturm WA. The measurement of early bactericidal activity. In: Malin A, McAdam K, editors. Bailliere's clinical infectious diseases: mycobacterial diseases (part II). Bailliere Tindall; London, UK: 1997. p. 185-206
   Google Scholar
• Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand J Infect Dis 2001;33(6):466-9
   PubMedGoogle Scholar
• Sirgel F, Venter A, Mitchison D. Sources of variation in studies of the early bactericidal activity of antituberculosis drugs. J Antimicrob Chemother 2001;47(2):177-82
   PubMed Web of Science ®Google Scholar
• Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001;1:2
   PubMedGoogle Scholar
• Sloan DJ, Corbett EL, Butterworth AE, et al. Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings. J Clin Microbiol 2012;50(7):2315-20
   PubMed Web of Science ®Google Scholar
• Peres RL, Maciel EL, Morais CG, et al. Comparison of two concentrations of NALC-NaOH for decontamination of sputum for mycobacterial culture. Int J Tuberc Lung Dis 2009;13(12):1572-5
   PubMedGoogle Scholar
• Kolwijck E, Mitchell M, Venter A, et al. Short-term storage does not affect the quantitative yield of Mycobacterium tuberculosis in sputum in early-bactericidal-activity studies. J Clin Microbiol 2013;51(4):1094-8
   PubMedGoogle Scholar
• Wallis RS, Phillips M, Johnson JL, et al. Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials. Antimicrob Agents Chemother 2001;45(4):1302-4
   PubMed Web of Science ®Google Scholar
• Wallis RS, Perkins M, Phillips M, et al. Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment. J Infect Dis 1998;178(4):1115-21
   PubMed Web of Science ®Google Scholar
• Wallis RS, Doherty TM, Onyebujoh P, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2009;9(3):162-72
   PubMed Web of Science ®Google Scholar
• Wallis RS, Jakubiec W, Mitton-Fry M, et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS ONE 2012;7(1):e30479
   PubMed Web of Science ®Google Scholar
• Desjardin LE, Perkins MD, Wolski K, et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med 1999;160(1):203-10
   PubMed Web of Science ®Google Scholar
• Li L, Mahan CS, Palaci M, et al. Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy. J Clin Microbiol 2001;48(1):46-51
   Google Scholar
• Honeyborne I, McHugh TD, Phillips PP, et al. Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. J Clin Microbiol 2011;49(11):3905-11
   PubMed Web of Science ®Google Scholar
• Blakemore R, Nabeta P, Davidow AL, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med 2011;184(9):1076-84
   PubMedGoogle Scholar
• Kayigire XA, Friedrich SO, Venter A, et al. Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity. J Clin Microbiol 2013;51(6):1894-8
   PubMedGoogle Scholar
• Donald PR, Sirgel FA, Kanyok TP, et al. Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 2000;44(12):3285-7
   PubMedGoogle Scholar
• Donald PR, Sirgel FA, Venter A, et al. The early bactericidal activity of streptomycin. Int J Tuberc Lung Dis 2002;6:693-8
   PubMed Web of Science ®Google Scholar